Arrhythmia, SARS-CoV-2 Infection
Conditions
Keywords
COVID-19, ECG, Torsade de pointe, QT interval
Brief summary
Cardiac involvement has been described in Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) infection. Although there are no approved drugs to prevent or treat SARS-CoV-2 infection at present time, several medications used have the potential to increase QT interval and eventually provoke torsades de pointe. The investigators therefore create a study that include all patients with SARS-CoV-2 infection having an electrocardiogram (ECG). The investigators evaluate the percentage of patients with ECG abnormalities, describe the abnormalities and evaluate the occurrence of syncope, ventricular arrhythmia and corrected QT (cQT) interval modification in patients receiving treatment.
Detailed description
In patients with SARS-CoV-2 infection, the investigators analyze baseline ECG as well as follow-up ECG. Patients followed by Bordeaux University Hospital for COVID-19 can be included. ECG are digitized in the computerized patient file (DxCARE) for further analysis.
Interventions
DIAGNOSTIC_TESTECG data analysis
Baseline ECG as well as follow-up ECG are analysed
DRUGTreatment data collect
Baseline treatment data as well as follow-up treatment data are collected
BIOLOGICALBiological check-up data collect
Baseline Biological check-up data as well as follow-up data are collected
OTHERCollection of clinical events of interest
Clinical events of interest at the baseline as well as follow-up clinical events are collected
Sponsors
University Hospital, Bordeaux
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients over 18 years of both gender, * Followed by Bordeaux University Hospital for SARS-CoV-2 infection with a cardiac monitoring or ECG realized. * Non opposition expressed.
Exclusion criteria
* Minor, * Inability to understand the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of ECGs abnormalities in patients SARS-CoV-2 infection | Day 0 | Percentage of ECGs with abnormalities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of PR, QRS and cQT interval | Baseline and 1 month | The evolution of interval is measured in seconds for patients receiving drugs interfering with cardiac electrophysiology for SARS-CoV-2 infection |
| Rate of syncope during treatment | Baseline and 1 month | The number of syncope is measured during the treatment |
| Rate of cardiac death during treatment | Baseline and 1 month | The number of cardiac death is measured during the treatment |
| Rate of arrhythmia during treatment | Baseline and 1 month | The number of arrhythmia is measured during the treatment |
Countries
France
Outcome results
None listed